Iradimed Co (IRMD)vsNovartis AG ADR (NVS)
IRMD
Iradimed Co
$93.07
-0.53%
HEALTHCARE · Cap: $1.18B
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 65473% more annual revenue ($56.58B vs $86.28M). IRMD leads profitability with a 27.4% profit margin vs 23.9%. NVS appears more attractively valued with a PEG of 3.93. IRMD earns a higher WallStSmart Score of 61/100 (C+).
IRMD
Buy61
out of 100
Grade: C+
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IRMD.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 32.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Keeps 27 of every $100 in revenue as profit
Earnings expanding 22.1% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 12.1x book value
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 32.9%. Revenue growth of 12.6% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, Piotroski F-Score. A P/E of 50.3x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
IRMD profiles as a mature stock while NVS is a declining play — different risk/reward profiles.
IRMD carries more volatility with a beta of 0.91 — expect wider price swings.
IRMD is growing revenue faster at 12.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
IRMD scores higher overall (61/100 vs 49/100), backed by strong 27.4% margins and 12.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?